Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Exclusion Criteria

• •Other serious or significant illnesses.
• •Resected cerebral metastases.
• •Ocular melanoma.
• •Other malignancy within last 3 years, except for treated non-melanoma skin cancer and cervical cancer in situ.
• •Using immunosuppressive drugs.
• •Anticoagulation.
• •Known HIV positivity.
• •Chemotherapy or radiation therapy in last four weeks (6 weeks for nitrosourea drugs).
• •Not available for immunological and clinical follow-up assessments.
• •Participation in prior clinical trial involving an investigational agent within last 4 weeks.
• •Previous isolated limb perfusion (ILP).
• •Pregnancy or breastfeeding.
• •Refusal or inability to use effective means of contraception for women of childbearing potential.
• •Mental impairment that may compromise ability to give informed consent and to comply with study requirements.